Lipidated Protein Production in E. coli via Genetic Adaptation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
E. coli strains are not suitable for producing lipidated proteins, as they either do not lipidate proteins or do so poorly, limiting the effectiveness of vaccine production using recombinant technology.
Innovation Solution
Utilizing E. coli strains adapted for membrane protein expression, such as C41(DE3) and C43(DE3), to produce lipidated proteins by transforming them with an expression plasmid encoding a naturally lipidated protein and culturing them to express the protein in lipidated form, followed by isolation and confirmation of lipidation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If E. coli is used for producing modified proteins, then recombinant technology can be applied, but the protein lipidation is insufficient or absent
Solution Approach 1:
The patent changes the genetic parameters of E. coli by introducing specific mutations (e.g., in the lipoA gene or other lipidation-related genes) to enable the bacterium to perform lipidation. This transforms E. coli from a system that cannot lipidate to one that can, resolving the contradiction between ease of recombinant production and precision of lipidation.
Solution Approach 2:
The patent introduces an intermediary system - likely a plasmid or genetic construct - that carries the lipidation capability genes into E. coli. This intermediary enables the host bacterium to acquire the necessary enzymatic machinery for lipidation while maintaining the ease of recombinant protein production.
2Productivity
If E. coli is used for producing lipidated proteins, then production scale can be increased, but the lipidation level remains poor
Solution Approach 1:
The patent optimizes genetic parameters by introducing mutations that enhance lipidation efficiency. By changing the enzymatic parameters of lipidation-related genes, the system achieves high-level lipidation while maintaining high productivity at large production scales.
Solution Approach 2:
The patent replaces the natural, limited lipidation capability of wild-type E. coli with an enhanced, engineered lipidation system. This substitution of the biological mechanism enables both high productivity and high lipidation levels simultaneously.
Data Source
AI summary
Production of a lipidated protein in an E. coli strain adapted to membrane protein expression.